HC Wainwright Issues Optimistic Estimate for RLMD Earnings

Relmada Therapeutics, Inc. (NASDAQ:RLMD) – Research analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Relmada Therapeutics in a research report issued on Friday, August 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.25). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Relmada Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Relmada Therapeutics’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.52) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at ($0.06) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Relmada Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.00.

Relmada Therapeutics Stock Down 8.1%

Shares of Relmada Therapeutics stock opened at $4.54 on Tuesday. The firm has a market cap of $484.28 million, a price-to-earnings ratio of -5.04 and a beta of 0.46. Relmada Therapeutics has a 52-week low of $0.55 and a 52-week high of $8.00. The company’s 50-day simple moving average is $6.01 and its 200-day simple moving average is $5.95.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RLMD. ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics by 1,364.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 451,918 shares of the company’s stock valued at $3,145,000 after acquiring an additional 421,052 shares in the last quarter. Commodore Capital LP purchased a new position in Relmada Therapeutics during the first quarter worth $4,412,000. Janus Henderson Group PLC raised its holdings in shares of Relmada Therapeutics by 52.2% in the first quarter. Janus Henderson Group PLC now owns 11,063,862 shares of the company’s stock worth $76,892,000 after acquiring an additional 3,793,862 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Relmada Therapeutics in the fourth quarter worth $744,000. Finally, Knott David M Jr purchased a new stake in shares of Relmada Therapeutics in the first quarter valued at $3,058,000. 45.24% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: HC Wainwright reduced its projected losses for every reported period. Estimates improved to $(0.60) EPS for fiscal 2026 from $(0.96), $(0.61) for fiscal 2027 from $(1.00), $(0.52) for fiscal 2028 from $(0.85), $(0.58) for fiscal 2029 from $(0.95), and $(0.06) for fiscal 2030 from $(0.32). The revisions suggest stronger expected operating performance and a faster path toward profitability.
• Positive Sentiment: Quarterly forecasts were also raised, including Q3 and Q4 2026 EPS to $(0.14), Q1 2027 to $(0.13), Q2 2027 to $(0.14), Q3 2027 to $(0.16), and Q4 2027 to $(0.17), all representing narrower projected losses than previously expected.
• Positive Sentiment: The $12 price target implies substantial upside from the recent trading level near $4.54, providing a bullish valuation signal if Relmada meets the revised forecasts.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.